A Look at FDA's FY2018 Generic Drug Performance

Eight months into Fiscal 2018, the US Food and Drug Administration (FDA) is on target to approve a similar number of generic drugs as it did the previous yea. In addition to FDA’s focus on boosting generic drug competition as a means of addressing prescription drug spending, Fiscal 2018 marks the first year of the agency's second generic drug user fee   program, which features new performance goals and program enhancements.